Journal
MICROBIAL PATHOGENESIS
Volume 178, Issue -, Pages -Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.micpath.2023.106033
Keywords
Pseudomonas aeruginosa; OprF; PcrV; Flagellin; Acute pneumonia
Categories
Ask authors/readers for more resources
The study shows that a chimeric vaccine including PcrV, FlaA, FlaB, and OprF (PABF) protein can induce a robust immune response, reduce bacterial burden, and improve survival after P. aeruginosa infection. It exhibits broad-spectrum immunity and holds promise as a candidate for treating and controlling P. aeruginosa infections.
Pseudomonas aeruginosa is an important and hazardous nosocomial pathogen in respiratory tract infections and rapidly achieves antibiotic resistance, so it is necessary to develop an effective vaccine to combat the infection. The Type III secretion system (T3SS) protein P. aeruginosa V-antigen (PcrV), outer membrane protein F (OprF), and two kinds of flagellins (FlaA and FlaB) all play important roles in the pathogenesis of P. aeruginosa lung infection and its spread into deeper tissues. In a mouse acute pneumonia model, the protective effects of a chimer vaccine including PcrV, FlaA, FlaB, and OprF (PABF) protein were investigated. PABF immunization prompted robust opsonophagocytic titer of IgG antibodies and decreased bacterial burden, and improved survival after-ward intranasal challenge with ten times 50% lethal doses (LD50) of P. aeruginosa strains, indicating its broad-spectrum immunity. Moreover, these findings showed a promise chimeric vaccine candidate to treat and control P. aeruginosa infections.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available